|The GALNT18 n/a (Catalog #MBS644814) is an Antibody produced from Mouse and is intended for research purposes only. The product is available for immediate purchase. The GALNT18 (Polypeptide N-acetylgalactosaminyltransferase 18, Polypeptide GalNAc Transferase-like Protein 4, GalNAc-T-like Protein 4, pp-GaNTase-like Protein 4, Polypeptide N-acetylgalactosaminyltransferase-like Protein 4, Protein-UDP acetylgalactosaminyltra reacts with Human and may cross-react with other species as described in the data sheet. MyBioSource\'s GALNT18 can be used in a range of immunoassay formats including, but not limited to, ELISA (EL/EIA).
Suitable for use in ELISA.
Dilution: Sandwich ELISA: The detection limit is~0.3ng/ml as a capture antibody. Researchers should empirically determine the suitability of the GALNT18 n/a for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process. The amino acid sequence is listed below:
SQQIHVGILS PTVDDDDNRC LVDVNSRPRL TECSYAKAKR MKLHWQFSQG GPIQNRKSKR CLELQENSDL EFGFQLVLQK CSGQHWSITN VLRSL*.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
May catalyze the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor.
Immunogen: Partial recombinant protein corresponding to aa511-606 from human GALNTL4 (NP_940918) with GST tag. MW of the GST tag alone is 26kD. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing GALNT18 are readily searchable from our website. Different antibodies against the same target such as GALNT18 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.